Dr. Reddy's Laboratories (RDY) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Is TAK or RDY more profitable?

Dr. Reddy's Laboratories has a net margin of 17.81% compared to Takeda Pharmaceutical's net margin of 6.49%. Dr. Reddy's Laboratories' return on equity of 18.53% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	6.49%	10.00%	4.78%
Dr. Reddy's Laboratories	17.81%	18.53%	13.01%

Which has better earnings & valuation, TAK or RDY?

Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.20B	1.46	$994.06M	$0.58	22.32
Dr. Reddy's Laboratories	$3.35B	3.71	$668M	$0.63	23.82

Is TAK or RDY a better dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 4.1%. Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays out 91.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Reddy's Laboratories pays out 12.8% of its earnings in the form of a dividend.

Do insiders & institutionals have more ownership in TAK or RDY?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk & volatility, TAK or RDY?

Takeda Pharmaceutical has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Does the media prefer TAK or RDY?

In the previous week, Dr. Reddy's Laboratories had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for Dr. Reddy's Laboratories and 1 mentions for Takeda Pharmaceutical. Dr. Reddy's Laboratories' average media sentiment score of 0.86 beat Takeda Pharmaceutical's score of 0.74 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer TAK or RDY?

Dr. Reddy's Laboratories has a consensus target price of $17.00, suggesting a potential upside of 14.03%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dr. Reddy's Laboratories	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community favor TAK or RDY?

Dr. Reddy's Laboratories received 221 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 59.33% of users gave Dr. Reddy's Laboratories an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Dr. Reddy's Laboratories	Outperform Votes 321 59.33%	Underperform Votes 220 40.67%

Summary

Dr. Reddy's Laboratories beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.